Tyra Biosciences, Inc. 10-Q

Item 2 . Unregistered Sales of Equity Securities and Use of Proceeds Unregistered Sales of Equity Securities None. Use of Proceeds from Initial Public Offering On September 14, 2021, our registration statement on Form S-1 (File No. 333- 258970) was declared effective by the SEC for our IPO. At the closing of the offering on September 17, 2021, we sold 12,420,000 shares of common stock, which included the exercise in full by the underwriters of their option to purchase 1,620,000 additional shares, at an initial public offering price of $16.00 per share and received gross proceeds of $198.7 million, which resulted in net proceeds to us of approximately $181.2 million , after deducting underwriting discounts and commissions of approximately $13.9 million and offering-related transaction costs of approximately $3.6 million. None of the expenses associated with the IPO were paid to directors, officers, persons owning 10% or more of any class of equity securities, or to their associates, or to our affiliates. BofA Securities, Inc., Jefferies LLC, and Cowen and Company, LLC acted as joint book-running managers for the offering. There has been no material change in the planned use of proceeds from our IPO from that described in the Prospectus. Issuer Repurchases of Equity Securities None. Item 3 . Defaults Upon Senior Securities Not applicable. Item 4 . Mine Safety Disclosures Not applicable.